HIF1A and neoplasm: A meta-analysis of nine studies (1103 subjects) found that half of GC patients have HIF-1α-expressing tumours associated with lower five-year survival, deeper invasion, higher lymphatic/vascular invasion risk, and advanced TNM stage [56].